Meeting
2018 Genitourinary Cancers Symposium
ProBio II: An adaptive and randomized multi-arm biomarker driven phase 2 study in men with castrate resistant prostate cancer (CRPC).
Authors
Henrik Gronberg
Karolinska Institutet, Stockholm, Sweden
Henrik Gronberg , Martin Eklund , Johan Lindberg , Anders Ullén , Anders Bjartell , Ove Andren , David Robinson , Ingela Franck Lissbrant , Gunilla Enblad , Olof Stahl , Camilla Thellenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS397)
DOI
10.1200/JCO.2018.36.6_suppl.TPS397
Abstract #
TPS397
Poster Bd #
M17
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Justin Shaya
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy.
First Author: Aishwarya Subramanian
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2023 ASCO Genitourinary Cancers Symposium
BMX inhibition and HSD3B1-driven resistance in prostate cancer in the Maverick trial.
First Author: Nima Sharifi